The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy

Abstract

Purpose: W hen used in the second-line setting, singleagent chemotherapy has produced response rates of more than 10% or median survival times greater than 4 months. W e studied the safety and efficacy of using second-line single docetaxel (75 mg/m 2 ) for advanced NSCLC patients who were previously treated with platinum-based chemotherapy in Korea.Materials and Methods: Thirty-three patients with advanced NSCLC received chemotherapy from May 2002 to January 2005. W e retrospectively reviewed the charts of these patients. The patients received 75 mg/m 2 of doxetaxel on day 1 and this was repeated at 3-week intervals.Results: The median age was 63 years (range: 42～77 years); 16 patients had adenocarcinoma and 8 patients had squamous cell carcinoma. The median number of cycles was 4 (range: 1～7 cycles). Of the 33 patients, 6 patients had partial responses, 13 patients had stable disease and 14 patients had progressive disease. The response rate was 18.2% . The median overall survival was 11 months (range: 7～15 months), and the median progression free survival was 5 months (range: 3～7 months). The median response duration was 5 months (range: 4～9 months). A total of 137 cycles were evaluated for toxicity. W e observed grade 3 or 4 neutropenia in 79 cycles (57.6% ), grade 3 or 4 leukopenia in 46 cycles (33.6% ), and grade 3 febrile neutropenia in 2 cycles (1.5% ). The median nadir day was day 9 (range: day 5～ 19), and the median number of G-CSF injections was 2 (range: 0～6). The most common non-hematologic toxicities were myalgia/arthralgia and neurotoxicity, but any grade 3 or 4 non-hematologic toxicity was not observed. The major toxicity of this therapy was neutropenia. The absolute neutrophil count decreased relatively rapidly, but neutropenic fever or related infection was rare. There were no treatment-related deaths.Conclusion: These results revealed a satisfactory response rate (18.2% ) with using docetaxel as the secondline chemotherapy for NSCLC. The second-line docetaxel was an active and well-tolerated regimen in patients with advanced NSCLC pretreated with platinum-based chemotherapy. (Cancer Res Treat. 2005;37:339-343)

Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study

“…However, the PFS benefit was only 3 months for this group of patients [ 25 – 27 ]. Previous studies have also shown a low ORR ranging between 9 and 18% for patients who received docetaxel as second-line regimen after progression from first-line platinum-based chemotherapy [ 25 – 28 ]. Thus, an alternative second-line regimen that could improve the clinical and survival outcomes of this patient population after progression from chemotherapy remains an unmet need.…”

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

“…This trial established the superiority of docetaxel, at the intermediate dose of 75 mg/m 2 , for the response rate, the time to progression and the overall survival of the study patients. Shim et al reported that 75 mg/m 2 of docetaxel monotherapy every 3 week was also effective in a Korean population with a response rate of 18.2% and a median survival time of 11 months 16) .…”

Weekly Low-Dose Docetaxel for Salvage Chemotherapy in Pretreated Elderly or Poor Performance Status Patients with Non-small Cell Lung Cancer

“…During the initial introduction of docetaxel, it was routinely administered once every 3 weeks. However, although docetaxel was effective salvage treatment in patients previously treated with platinum-based chemotherapy, hematological toxicity was substantial with the 3-week treatment schedule; grade 3 or 4 neutropenia was observed in 54-67% of patients treated with a 75 mg/m 2 dose of docetaxel ( 3 , 4 , 8 ). Even at a 60 mg/m 2 dose, grade 3 or 4 neutropenia developed in more than 80% of patients in a Japanese trial ( 9 ).…”